Illumina has just reached its 10th anniversary in the Long Term Global Growth portfolio. The company has played a significant role in driving down the costs of gene sequencing. In 2002, it cost about $100m to process the human genome. Today it can be done for less than $600. Last year, 10 days after the first Covid-19 case, the virus was sequenced on an Illumina system and the code was shared with scientists around the world to develop a vaccine. Illumina has become key to helping scientists diagnose disease more quickly, enabling lifesaving solutions.

Like other companies in the portfolio, Illumina's journey has not been smooth. Its share price fell by more than a third on six occasions. One drop occurred in 2012 during Roche's attempted takeover. We opposed the bid. Despite the attractive offer, it did not reflect the immense potential for Illumina's technology to improve the lives of hundreds of millions of people. Safeguarding the company's independence was the correct action for a long-term investor and we now have the benefit of a long-standing relationship.

Mark Urquhart recently met with CEO Francis deSouza to discuss progress, and wrote the following:

**Reflections**

December 2021

Having met with deSouza last year to understand more about Illumina's slowing growth rate, today's picture is very different and much more positive. In many ways, this illustrates the dangers of putting too much emphasis on any spot numbers. I think we may be much closer to the tipping point for genomics than it would have been fair to expect before the pandemic.

The raw numbers are striking. The most recent top-line growth rate is 40 per cent and the company now expects growth of 36 per cent for 2021. That is double its expectation at the start of the year. Even allowing for some bounceback from low growth rates around the start of the pandemic, these numbers are striking and beg the question of whether we are transitioning to sustainably higher structural growth, which has been the alluring prospect at Illumina for many years.

In this context, I thought deSouza's observations were noteworthy. His central message was that the pandemic had "accelerated the development of genomics by at least five years". The thought of having hundreds of millions of mRNA vaccines in people's arms was a pipedream two years ago. Now it is a reality, and in making this leap forward some of the biggest regulatory bars have been crossed, making future approvals meaningfully easier.
The bottom line is that sequencing is now central and has crossed its Rubicon in terms of adoption. He drew a stark contrast between how the Zika outbreak was dealt with and how Covid-19 and its variants are being tackled, describing the change as transformational. Zika used the old model, where after detection through unexpected death, scientists would fly in and set up sequencing machines to slowly piece together what had happened. Today sequencing is an embedded practice in Africa, South America and elsewhere, and every nation uses the process to determine its health and public policies. He also sees a common aim of making this the last pandemic.

There are two major consequences of this positive change. The first is that its customer numbers are rising rapidly. Illumina added 50 per cent more new customers in the first three quarters of this year compared to 2020 as a whole, as general awareness of genomics increased. In effect, the pandemic has decreased barriers to adoption, which should create lasting uplift in recurring revenues. The second consequence of the greater ubiquity of sequencers is increased use across a spectrum of diseases. In deSouza’s view, this is the second era for Illumina. The first was entering clinics in 2013. Today it’s moving from primary oncology to embracing the top 10 big diseases, including cardiovascular and pulmonary ailments. In his words, “genomics is entering the mainstream much more broadly than before”, and the use for drug discovery has moved from speciality biotech to big pharma.

I feel much more enthused about Illumina’s long-term prospects than I did at the start of 2020, with the pandemic showing genomics is a powerful force for good. I liked the fact that deSouza was much more direct in his comments. He talked about Illumina transitioning into becoming a multi-omics company and the exciting opportunity Illumina had to recreate a Roche for the 21st century. With only 0.02 per cent of humans sequenced, little to no competition and strong public and private health tailwinds, Illumina is well-positioned to dominate this market. We’re excited to support the company and be part of this journey. We remind ourselves that patience is key.
Important information and risk factors

Past performance is not a guide to future results. Changes in the investment strategies, contributions or withdrawals may materially alter the performance and results of the portfolio. All investment strategies have the potential for profit and loss.

Risk factors
The views expressed in this article are those of the authors and should not be considered as advice or a recommendation to buy, sell or hold a particular investment. They reflect personal opinion and should not be taken as statements of fact nor should any reliance be placed on them when making investment decisions.

Any stock examples and images used in this article are not intended to represent recommendations to buy or sell, neither is it implied that they will prove profitable in the future. It is not known whether they will feature in any future portfolio produced by us. Any individual examples will represent only a small part of the overall portfolio and are inserted purely to help illustrate our investment style.

This article contains information on investments which does not constitute independent research. Accordingly, it is not subject to the protections afforded to independent research, but is classified as advertising under Art 68 of the Financial Services Act ('FinSA') and Baillie Gifford and its staff may have dealt in the investments concerned.

All information is sourced from Baillie Gifford & Co and is current unless otherwise stated. The images used in this article are for illustrative purposes only.

Important information
Baillie Gifford & Co and Baillie Gifford & Co Limited are authorised and regulated by the Financial Conduct Authority (FCA). Baillie Gifford & Co Limited is an Authorised Corporate Director of OEICs.

Baillie Gifford Overseas Limited provides investment management and advisory services to non-UK Professional/Institutional clients only. Baillie Gifford Overseas Limited is wholly owned by Baillie Gifford & Co. Baillie Gifford & Co and Baillie Gifford Overseas Limited are authorised and regulated by the FCA in the UK.

Persons resident or domiciled outside the UK should consult with their professional advisers as to whether they require any governmental or other consents in order to enable them to invest, and with their tax advisers for advice relevant to their own particular circumstances.

Financial Intermediaries
This communication is suitable for use of financial intermediaries. Financial intermediaries are solely responsible for any further distribution and Baillie Gifford takes no responsibility for the reliance on this document by any other person who did not receive this document directly from Baillie Gifford.

Europe
Baillie Gifford Investment Management (Europe) Limited provides investment management and advisory services to European (excluding UK) clients. It was incorporated in Ireland in May 2018 and is authorised by the Central Bank of Ireland. Baillie Gifford Investment Management (Europe) Limited provides investment management and advisory services to European (excluding UK) clients. It was incorporated in Ireland in May 2018 and is authorised by the Central Bank of Ireland. Through its MiFID passport, it has established Baillie Gifford Investment Management (Europe) Limited (Frankfurt Branch) to market its investment management and advisory services and distribute Baillie Gifford Worldwide Funds plc in Germany.

Similarly, it has established Baillie Gifford Investment Management (Europe) Limited (Amsterdam Branch) to market its investment management and advisory services and distribute Baillie Gifford Worldwide Funds plc in The Netherlands. Baillie Gifford Investment Management (Europe) Limited also has a representative office in Zurich, Switzerland pursuant to Art. 58 of the Federal Act on Financial Institutions (‘FinIA’). It does not constitute a branch and therefore does not have authority to commit Baillie Gifford Investment Management (Europe) Limited. It is the intention to ask for the authorisation by the Swiss Financial Market Supervisory Authority (FINMA) to maintain this representative office of a foreign asset manager of collective assets in Switzerland pursuant to the applicable transitional provisions of FinIA.

Baillie Gifford Investment Management (Europe) Limited is a wholly owned subsidiary of Baillie Gifford Overseas Limited, which is wholly owned by Baillie Gifford & Co.

Hong Kong
Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲 (香港) 有限公司 is wholly owned by Baillie Gifford Overseas Limited and holds a Type 1 and a Type 2 licence from the Securities & Futures Commission of Hong Kong to market and distribute Baillie Gifford’s range of collective investment schemes to professional investors in Hong Kong. Baillie Gifford Asia (Hong Kong) Limited 柏基亞洲 (香港) 有限公司 can be contacted at Suites 2713-2715, Two International Finance Centre, 8 Finance Street, Central, Hong Kong, Telephone +852 3756 5700.

South Korea
Baillie Gifford Overseas Limited is licensed with the Financial Services Commission in South Korea as a cross border Discretionary Investment Manager and Non-discretionary Investment Adviser.

Japan
Mitsubishi UFJ Baillie Gifford Asset Management Limited (‘MUBGAM’) is a joint venture company between Mitsubishi UFJ Trust & Banking Corporation and Baillie Gifford Overseas Limited. MUBGAM is authorised and regulated by the Financial Conduct Authority.
Important information and risk factors

Australia
Baillie Gifford Overseas Limited (ARBN 118 567 178) is registered as a foreign company under the Corporations Act 2001 (Cth) and holds Foreign Australian Financial Services Licence No 528911. This document is provided to you on the basis that you are a ‘wholesale client’ within the meaning of section 761G of the Corporations Act 2001 (Cth) (‘Corporations Act’). Please advise Baillie Gifford Overseas Limited immediately if you are not a wholesale client. In no circumstances may this document be made available to a ‘retail client’ within the meaning of section 761G of the Corporations Act.

This document contains general information only. It does not take into account any person’s objectives, financial situation or needs.

South Africa
Baillie Gifford Overseas Limited is registered as a Foreign Financial Services Provider with the Financial Sector Conduct Authority in South Africa.

North America
Baillie Gifford International LLC is wholly owned by Baillie Gifford Overseas Limited; it was formed in Delaware in 2005 and is registered with the SEC. It is the legal entity through which Baillie Gifford Overseas Limited provides client service and marketing functions in North America. Baillie Gifford Overseas Limited is registered with the SEC in the United States of America.

The Manager is not resident in Canada, its head office and principal place of business is in Edinburgh, Scotland. Baillie Gifford Overseas Limited is regulated in Canada as a portfolio manager and exempt market dealer with the Ontario Securities Commission (‘OSC’). Its portfolio manager licence is currently passported into Alberta, Quebec, Saskatchewan, Manitoba and Newfoundland & Labrador whereas the exempt market dealer licence is passported across all Canadian provinces and territories. Baillie Gifford International LLC is regulated by the OSC as an exempt market and its licence is passported across all Canadian provinces and territories. Baillie Gifford Investment Management (Europe) Limited (‘BGE’) relies on the International Investment Fund Manager Exemption in the provinces of Ontario and Quebec.

Israel
Baillie Gifford Overseas is not licensed under Israel’s Regulation of Investment Advising, Investment Marketing and Portfolio Management Law, 5755–1995 (the Advice Law) and does not carry insurance pursuant to the Advice Law. This document is only intended for those categories of Israeli residents who are qualified clients listed on the First Addendum to the Advice Law.

Oman
Baillie Gifford Overseas Limited (‘BGO’) neither has a registered business presence nor a representative office in Oman and does not undertake banking business or provide financial services in Oman. Consequently, BGO is not regulated by either the Central Bank of Oman or Oman’s Capital Market Authority. No authorization, licence or approval has been received from the Capital Market Authority of Oman or any other regulatory authority in Oman, to provide such advice or service within Oman. BGO does not solicit business in Oman and does not market, offer, sell or distribute any financial or investment products or services in Oman and no subscription to any securities, products or financial services may or will be consummated within Oman. The recipient of this document represents that it is a financial institution or a sophisticated investor (as described in Article 139 of the Executive Regulations of the Capital Market Law) and that its officers/employees have such experience in business and financial matters that they are capable of evaluating the merits and risks of investments.

Qatar
The materials contained herein are not intended to constitute an offer or provision of investment management, investment and advisory services or other financial services under the laws of Qatar. The services have not been and will not be authorised by the Qatar Financial Markets Authority, the Qatar Financial Centre Regulatory Authority or the Qatar Central Bank in accordance with their regulations or any other regulations in Qatar.